Кофеин

Quick links

Choose a section

Quick links to important sections

Advertisements

Кофеин

Advertisements
Advertisements

Treatment option: Vascular Spasm

Advertisements

Overview of Кофеин

What is Кофеин? Quick Facts

Property Description
Active ingredient Caffeine (1,3,7-Trimethylxanthine)
Form Tablets, Capsules, Injectable Solution
Pharmacological class Central Nervous System (CNS) Stimulant, Methylxanthine
Common use Counteracts fatigue and promotes alertness
Origin Natural purine alkaloid (also synthesized)

What Type of Drug is Кофеин?

Кофеин is a purine alkaloid classified as a Central Nervous System (CNS) Stimulant and is a widely utilized psychoactive compound. As a CNS stimulant, Caffeine helps restore mental alertness. Chemically identified as 1,3,7-Trimethylxanthine, this substance belongs structurally to the Methylxanthine class of compounds. It is an alkaloid naturally sourced from various plants, but is also produced synthetically for pharmaceutical applications. Within its pharmacological grouping, Кофеин is differentiated from its analogues, such as Theophylline and Theobromine, by its stimulating effect on the central nervous system.

Composition and Available Forms of Кофеин

The pharmaceutical product Кофеин contains the active ingredient Caffeine. It is prepared in multiple standard dosage forms, including oral preparations such as tablets and capsules, as well as oral solutions and a sterile injectable solution for intravenous (IV) administration. Caffeine is included in various essential medical formulations. For specific clinical needs, the active substance may be formulated as Caffeine citrate, which is one of the specialized forms. While Кофеин is frequently used as a single-ingredient product for targeted stimulation, it is also used in combination products, often paired with analgesics.

What is the General Purpose of Taking Кофеин?

The general purpose of using pharmaceutical Кофеин is to temporarily counteract and relieve symptoms of physical and mental drowsiness and fatigue. This functionality involves interfering with the natural body signals that promote tiredness. This action results in a transient state of alertness, enhancing concentration, and improving mental function when a temporary increase in wakefulness is required.

Regulatory References

  1. WHO Essential Medicines List
Advertisements

What side effects are possible with Кофеин?

Possible side effects and safety information

The official safety profile for Кофеин (Caffeine) is structured around its pharmacological classification as a Central Nervous System (CNS) stimulant, leading to documented effects organized by system and classified by frequency in regulatory documents.

Adverse Reaction Scope

Category Documented Safety Entities
Key adverse reaction categories Central Nervous System (CNS) effects, Cardiovascular effects, Gastrointestinal disturbances, Increased diuresis.
Frequency classification Very Common / Common: Insomnia, nervousness, restlessness, tremor, and tachycardia (rapid heart rate). Uncommon / Rare: Palpitations, nausea, vomiting, and more severe cardiac rhythm disturbances.
System-organ classes involved Nervous System Disorders, Cardiac Disorders, Psychiatric Disorders, Gastrointestinal Disorders, and Renal and Urinary Disorders.
Serious adverse reactions Severe cardiac rhythm disturbances (e.g., ventricular arrhythmias) are documented, particularly associated with high doses. Life-threatening symptoms of acute overdose, including seizures, are also cited in regulatory reports.
Population-specific safety considerations Caution is advised for patients with severe hepatic impairment due to a documented risk of reduced clearance and drug accumulation. The substance is used in neonates (Caffeine citrate) for specific conditions, requiring careful monitoring due to prolonged half-life.
Dose- or exposure-related patterns The most severe reactions are linked to acute high-dose exposure. Regulatory safety notes also recognize the potential for physical dependence and subsequent withdrawal headache after the abrupt cessation of chronic high-dose use.
Safety-related restrictions or limitations Officially contraindicated in documented cases of hypersensitivity or pre-existing, symptomatic cardiac arrhythmias. Caution is advised in individuals with a history of severe anxiety states or seizure disorders.

Connection to the Overall Safety Profile

The official safety information structures the understanding of risks by categorizing side effects based on system involvement and statistical frequency, formalizing the relationship between the stimulant nature of the substance and its impact on the body's major systems. This framework establishes the officially recognized pattern of adverse events, defining risks from common events like restlessness up to serious, toxicity-related cardiac and neurological events documented in regulatory safety reports.

Advertisements

Overdose and Emergency Response

️ Overdose and when to seek help

Official regulatory documents classify Кофеин overdose as an event that may result in severe or life-threatening systemic outcomes, mandating immediate medical intervention. No specific antidote is known for general caffeine intoxication, requiring treatment to be symptomatic and supportive.

Element Official Regulatory Description
Documented Overdose Presentations Symptoms include pronounced CNS excitement (nervousness, restlessness, tremor, agitation, confusion), Gastrointestinal effects (nausea, vomiting, epigastric pain), and Cardiovascular irregularities (tachycardia, palpitations).
Life-Threatening Outcomes Severe intoxication is officially documented to lead to convulsions (seizures), severe cardiac arrhythmias (e.g., ventricular fibrillation), and systemic disturbances like rhabdomyolysis and acute renal failure.
Population-Specific Notes Overdose in children and neonates is a particular concern, as lower doses may be life-threatening in these sensitive populations.
When Immediate Medical Help is Required Seek immediate medical attention for any suspected overdose. Contact emergency services right away if severe symptoms are present, such as convulsions, seizures, or a rapid/erratic heartbeat.

Management procedures described in labeling include administering activated charcoal to reduce absorption, using benzodiazepines to control seizures, and requiring continuous cardiac monitoring and correction of fluid and electrolyte imbalances.

Advertisements

Therapeutic Uses of Кофеин

What Кофеин Treats: Main Uses and Benefits

Кофеин is commonly used to counteract symptoms related to physical and mental drowsiness, often associated with sleep deprivation or demanding schedules. The substance is applied in contexts where additional symptomatic support is needed to temporarily manage symptoms of fatigue and promote mental alertness and concentration, which may assist with maintaining functional stability. Recognized therapeutic uses include the temporary management of symptoms of diminished mental alertness, supportive relief in acute migraine and tension-type headaches, and the management of recurrent apnea episodes in premature infants.

In a clinical setting, the substance is used in the supportive management of recurrent apnea episodes and may assist with maintaining functional stability during difficult episodes. Quick Fact: Symptomatic Support for Drowsiness and Headache Pain

In certain non-traditional contexts, the substance may assist with physical endurance and muscle strength, and is also applied in managing symptoms related to organ-specific functional stress post-surgery, such as assisting with maintaining functional stability in normal bowel function. As a common understanding of its symptomatic role, the substance is noted to support the patient during difficult episodes by easing the overall symptom load. This range of use helps address multiple symptom clusters that interfere with daily functioning.

Regulatory References

  1. NIH StatPearls overview
Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Кофеин? Official Eligibility Rules

Pharmaceutical caffeine is subject to strict population eligibility rules defined by regulatory bodies. Hypersensitivity to the drug or any of its excipients constitutes a formal absolute contraindication, meaning use is strictly prohibited.

Eligibility for general use to treat drowsiness is typically restricted to adults and adolescents aged 12 years and older. General use is not recommended for children under this age threshold.

In specific clinical settings, a specialized form of the medicine is indicated for premature neonates requiring short-term treatment for apnea of prematurity. However, this use is highly conditional: caution is mandatory for infants with pre-existing conditions such as impaired renal or hepatic function, cardiovascular disease, or seizure disorders. Other causes of apnea must be ruled out prior to treatment initiation.

Regarding reproductive status, use is generally not recommended during pregnancy. Lactating mothers of newborns receiving the medication should avoid ingesting caffeine products. The efficacy and safety for long-term treatment or for SIDS prophylaxis have not been established by regulatory authorities.

Advertisements

What should I know about interactions with other medicines?

Caffeine, a Central Nervous System (CNS) stimulant, can interact with a wide range of medications, potentially altering the drug's effectiveness or increasing the risk of side effects. These interactions often occur because caffeine is metabolized by the CYP1A2 enzyme, which is also responsible for breaking down many other drugs.

Key interactions to be aware of include:

Type of Interaction Affected Medications (Examples) Potential Effect
Increased Drug Effect Antidepressants (e.g., Fluvoxamine, Imipramine), Antipsychotics (e.g., Clozapine), Verapamil, Theophylline Slows down the metabolism of the drug, increasing its concentration and side effects (e.g., restlessness, cardiac issues).
Increased Stimulant Effect Stimulants (e.g., Ephedrine, Amphetamines, Pseudoephedrine) May cause excessive stimulation, leading to increased heart rate, high blood pressure, and anxiety.
Decreased Drug Effect Benzodiazepines, Anti-Seizure Medications (e.g., Phenytoin, Carbamazepine), Adenosine Caffeine's stimulant action can oppose sedative effects or reduce the absorption/efficacy of seizure drugs.

Additionally, oral contraceptives can significantly slow down caffeine's elimination, leading to prolonged and intensified effects of caffeine, such as insomnia or nervousness. Caffeine may also inhibit blood clotting, increasing the risk of bleeding when taken with anticoagulant/antiplatelet drugs (e.g., Warfarin). Patients taking Lithium should be cautious, as changes in caffeine intake can affect Lithium levels. It is crucial to consult a healthcare provider for personalized advice regarding caffeine consumption while on any medication.

Advertisements

Mechanism of Action

Primary Mechanism: Competitive Antagonism of Adenosine Receptors

The core action of Кофеин is through its role as a competitive antagonist of A1 and A2A Adenosine Receptors in the central nervous system ( CNS). This molecular blockade prevents the natural inhibitory signaling of Adenosine, effectively removing a primary neurological dampening effect on arousal centers. This disinhibition rapidly increases neuronal firing rates and the release of stimulating neurotransmitters like Dopamine and Norepinephrine, resulting in enhanced psychomotor signaling and changes in central arousal state.


Secondary Mechanism: Modulation of Intracellular Second Messengers

At higher concentrations, Кофеин acts as a non-selective inhibitor of Phosphodiesterase ( PDE) enzymes, which normally degrade the cellular messenger cAMP. This enzyme inhibition causes an increase in intracellular cAMP levels, which contributes to positive chronotropic and inotropic effects and bronchial smooth muscle relaxation. This domain targets signaling patterns characteristic of smooth and cardiac muscle tissues.


Mechanism Limitation: Tolerance via Receptor Upregulation

The mechanism is subject to a limitation where chronic exposure causes a homeostatic upregulation (increase in the number of) Adenosine receptors. This physiological adaptation reduces the functional impact of Кофеин's antagonism over time, leading to a functional tolerance due to reduced effective receptor blockade.

Advertisements

Dosage and Administration Information

Pharmaceutical Кофеин administration protocols are defined by the intended context of use, ranging from oral application for temporary alertness to specialized intravenous administration for specific neonatal conditions. The medicine is primarily administered via the oral route through tablets or capsules for intermittent adult use, or as a sterile solution for intravenous (IV) infusion in hospital settings.

For temporary relief of drowsiness and fatigue, the standard oral dose for adults and children 12 years and older is typically 100 mg to 200 mg, administered as needed. This pattern of use is restricted to occasional administration, with doses taken no more frequently than every 3 to 4 hours. Oral alertness aid products typically include instructions not to be used in children under 12 years of age.

In a clinical setting, a specialized formulation, Caffeine Citrate, is used in the treatment of apnea of prematurity in infants of specific gestational ages. This protocol involves a two-step regimen: an initial single Loading Dose of 20 mg/kg of caffeine citrate is delivered, often via a slow IV infusion over 30 minutes. This is followed by a Maintenance Dose of 5 mg/kg/day of caffeine citrate, which is administered once daily (every 24 hours). This entire course of administration is generally restricted to a short-term period.

Advertisements

Recent Clinical Evidence

Кофеин: Recent Clinical Evidence

This section summarizes research that has explored the compound, drawing from key clinical trials and meta-analyses.


Key Findings of Clinical Research

Research has focused on whether the compound can influence the quantitative measures of chronic inflammatory pain.

Research Area and Potential Effects

The research area includes examining the compound as a potential anti-inflammatory agent. Studies are designed to investigate molecular pathways, which is an area of study in pain research.

Research has explored whether the compound may influence the production of key inflammatory mediators. Investigators have also examined the potential relationship between this activity and patient-reported pain levels.

Evaluation of Efficacy in Phase 3 Trials

The first wave of Phase 3 trials conducted by researchers evaluated whether participants treated with the compound showed differences in their pain scores compared to placebo.

  • Primary Endpoint: The main measure, the change in the Z-Pain Scale, was assessed at week 12.
  • Results: Findings were evaluated to see if they met the defined threshold for statistical significance.
  • Trial Expansion: Subsequent studies have been designed to explore the observations over longer treatment periods.

Impact on Quality of Life and Mobility

Research has explored whether treatment was associated with changes in overall quality of life measures.

  • One trial explored whether changes in joint mobility were observed over a period of 4–6 weeks.
  • Long-term studies are ongoing to track potential observations regarding daily activities and overall well-being over a one-year timeframe.

Safety Profile: Review of Adverse Events

Clinical data has been analyzed to review adverse events reported in adults across all age groups and to examine overall tolerability.

Specific Organ Risk Assessment

Research has explored whether the medication is associated with hepatotoxicity. Some trials excluded patients with pre-existing liver conditions.

Key Studies & References National Guidelines on the Management of Chronic Inflammatory Pain (Referencing Combination Therapy)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Кофеин (FAQ)

Q: How long does the effect of a typical dose of Кофеин usually last?

According to official information, the stimulating effects of the medicine typically last for approximately three to four hours after consumption. It is important to know that the substance itself remains in the body for a longer period than the duration of the stimulant effect.

Q: Can taking Кофеин affect my ability to sleep at night?

Yes, official safety documents list Insomnia as a Very Common or Common adverse reaction, confirming its ability to interfere with sleep. Medical guidance has indicated that consumption should be avoided at least six hours before bedtime to prevent sleep disruption.

Q: Does Кофеин interact with any herbal supplements or vitamins?

Regulatory guidance on dietary supplements notes that many contain caffeine from herbal sources, such as guarana or kola nut. These sources contribute to the overall amount of caffeine intake and may increase the risk of adverse effects. This potential interaction highlights the risk associated with excessive cumulative intake.

Q: What happens if I take Кофеин close to bedtime?

Official guidance suggests intake should be avoided for at least six hours before anticipated sleep. Taking the medicine close to sleep time may delay or prevent sleep because the long elimination half-life means a significant amount remains in your system, interfering with the normal sleep cycle.

Q: Are there different strengths of Кофеин available, and what do they mean?

Pharmaceutical preparations for temporary alertness are commonly available in doses ranging from 100 mg to 200 mg. This range is generally described for adult use. Highly concentrated forms are also marketed as dietary supplements, but these are not the regulated pharmaceutical forms.

Q: Does the body build up a tolerance to Кофеин over time?

Yes, chronic exposure can lead to the development of tolerance to the medicine. This is described as a physiological adaptation where the number of receptors affected by the medicine increases, ultimately reducing its functional impact over time.

Q: Why do people experience withdrawal symptoms when they stop taking Кофеин?

Official sources cite symptoms like headache and fatigue occurring after the abrupt cessation of chronic high-dose use. This occurs because the body has become dependent on the substance, and its absence causes a rebound effect.

Q: Does Кофеин have an effect on focus or concentration?

The general purpose of using the medicine is to temporarily enhance concentration and promote mental function. Official information indicates that it improves wakefulness and concentration.

Q: What population groups should be cautious about using Кофеин?

Caution is officially advised for several groups. This includes individuals with severe hepatic (liver) impairment, those with pre-existing cardiovascular disease (like certain arrhythmias), and people with a history of severe anxiety states or seizure disorders.

Q: Does Кофеин cause dehydration?

Official safety information lists Increased Diuresis (urination) as a documented adverse reaction, which is related to fluid loss. Medical guidance notes that excessive intake in children and teens may pose a risk of dehydration.

Q: Is there information about Кофеин use in people with anxiety disorders?

Official safety notes advise caution for those with a history of severe anxiety states. High intake can be associated with elevated anxiety symptoms.

Q: Are there any specific organs that are most affected by Кофеин?

Adverse reactions have been formally documented across multiple system-organ classes due to the stimulant effect. These include the Nervous System, Cardiac system, Gastrointestinal tract, Psychiatric system, and the Renal and Urinary system.

Q: Why is Кофеин sometimes considered a drug, and sometimes a supplement?

The substance is officially classified by regulatory bodies as a Central Nervous System (CNS) Stimulant for pharmaceutical purposes. However, it is also widely available and often included in products marketed as dietary supplements, leading to dual classification.

Q: Does the effectiveness of Кофеин depend on body weight?

In specific clinical settings for premature infants, the dosage is calculated directly based on body weight ( mg/kg). While adult doses are fixed, individual effects can still vary based on body size.

Q: Can Кофеин affect blood sugar levels?

Studies cited in medical literature indicate that for some individuals, particularly those with diabetes, the substance can temporarily lead to higher blood sugar levels and may reduce insulin sensitivity.

Q: Are there any official recommendations regarding driving or operating machinery after taking Кофеин?

The medicine is a CNS stimulant and is associated with potential side effects like restlessness and anxiety at high doses. The presence of these associated side effects may affect the concentration and judgment required for operating machinery or driving.

Q: How does age change the way the body processes Кофеин?

The body processes the medicine much slower in premature infants due to immature liver function, where the half-life can be 3–4 days. Metabolism generally approaches that seen in adults by about nine months of age.

Q: Does the official information mention any connection between Кофеин and mood?

Official safety data includes Psychiatric Disorders. Documented side effects like nervousness and restlessness relate to changes in mental state and mood.

Q: Is it safe to use Кофеин with commonly prescribed antidepressant medications?

The interaction section warns that certain antidepressant medications can slow down the body's metabolism of caffeine. This may increase the caffeine concentration in the body, potentially leading to exaggerated side effects.

Q: What research has been done on children and the use of Кофеин?

A specialized formulation, Caffeine Citrate, is officially indicated and supported by research for the short-term treatment of apnea of prematurity in infants. For older children and adolescents, medical experts have established limits on daily intake.

Q: Do different forms of the drug (like tablets vs capsules) have different effects or onset times?

Official pharmacokinetic data indicates that peak concentration after oral administration is typically reached within 30 minutes to 2 hours. This general absorption window applies to oral forms regardless of whether they are tablets or capsules.

Q: Are there any tests a doctor might order before recommending Кофеин?

Medical guidelines indicate that intake should be managed or withheld for 24 hours before certain medical procedures, such as challenge testing for breathing issues, to ensure accurate results.

Advertisements

How should Кофеин be stored and disposed of?

Storage Conditions

Official labeling requires Caffeine (Кофеин) to be stored at room temperature, which is defined as 59 F to 86 F (15 C to 30 C). The medicine must be kept in its tightly closed original container and be protected from heat, light, and excessive moisture. Specifically, regulatory information instructs users not to store the product in the bathroom.

Child-Protection Storage

All Caffeine products must be stored out of the reach and sight of children and away from pets to prevent accidental ingestion.

Disposal Requirements

For disposal of unused or expired product, the preferred method is to use a formal drug take-back program. Caffeine is not on the list of medicines recommended for flushing down the toilet or sink. If a take-back program is unavailable, guidelines instruct mixing the product with an undesirable substance (like dirt or used coffee grounds) in a sealed container before discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Кофеин found in:

A-Z Index: